ALAMEDA, Calif., Jan 27, 2004 (BUSINESS WIRE) -- Calypte Biomedical Corporation (CYPT) , the developer and marketer of the only two FDA approved HIV-1 antibody tests for use with urine samples, today announced that management will host a conference call Thursday January 29 at 5:00 p.m. Eastern Time, to introduce new officers as well as provide an update on the Company's current activities.
The call can be accessed in the U.S. by dialing 800-299-7635 and outside of the U.S. by dialing 617-786-2901. The participant passcode is 81548662. The conference call will also be Web cast live at www.calypte.com. An audio replay of the call will be available, beginning approximately 1 hour after the conference call ends, by dialing 888-286-8010 in the US, or 617-801-6888 from outside of the U.S. The account code for the playback is 35928376. The webcast will also be available for replay on the company's website.
The webcast is also being distributed over CCBN's Investor Distribution Network to both institutional and individual investors. Individual investors can listen to the call through CCBN's individual investor center at www.fulldisclosure.com or by visiting any of the investor sites in CCBN's Individual Investor Network. Institutional investors can access the call via CCBN's password-protected event management site, StreetEvents (www.streetevents.com).
About Calypte Biomedical Corporation:
Calypte Biomedical Corporation, headquartered in Alameda, California, is a public healthcare company dedicated to the development and commercialization of urine-based diagnostic products and services for Human Immunodeficiency Virus Type 1 (HIV-1), sexually transmitted diseases and other infectious diseases. Calypte's tests include the screening EIA and supplemental Western Blot tests, the only two FDA-approved HIV-1 antibody tests that can be used on urine samples, as well as an FDA-approved serum HIV-1 antibody Western Blot test. The company believes that accurate, non-invasive urine-based testing methods for HIV and other infectious diseases may make important contributions to public health by helping to foster an environment in which testing may be done safely, economically, and painlessly. Calypte markets its products in countries worldwide through international distributors and strategic partners. Current product labeling including specific product performance claims can be found at www.calypte.com.
sertralin19
: Kommentar zum gestrigen Kursverlauf von Caly:
Today the stock closed lower with a lower high and a lower low. The volume is extremely low. The security price is trending up.
The uptrend is not very strong. You may try your chance once more and buy this stock now, but be careful! Do not expect big profits and you do not have to necessarily wait for the next signal for realization. Cautious investors should stay at the sidelines.
Thread abonnieren
